1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug conjugate (ADC) ...
1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in the 100-mg group, 1.92 kg (2.99%) in the 200-mg group, and 2.81 kg (5.46) in the ...
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ... 1. Dapagliflozin reduced the risk of hospitalization in patients with ...